Merck Sharp & Dohme LLC: Phase 3 study closed enrollment, 473 enrolled (Gastroesophageal Cancer)
Merck Sharp & Dohme LLC: Phase 3 study closed enrollment, 473 enrolled (Gastroesophageal Cancer). Its enrollment of 473 is above the median of 80 (89th percentile). Dated 13 days ago, it is in the active follow-up window. Score 100/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 473 · 89th percentile of 8,879 ClinicalTrialStartPulse records · 5.9x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) |
| NCT ID | NCT06356311 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Gastroesophageal Cancer |
| Intervention types | biological, drug |
| Target enrollment | 473 |
| Site countries | United States, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, France, Germany, Hong Kong, Israel |
| Posted | 2024-04-10 |
| Planned start | 2024-05-03 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-22 |
| Last update posted | 2026-10-22 |
| enrollment percentile | 89th of 8,879 (median 80, 5.9x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Merck Sharp & Dohme LLC
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of US records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Merck Sharp & Dohme + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-22
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Cancer Institute (NCI) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Merck Sharp & Dohme LLC and 2,512 US peers
- US ClinicalTrialStartPulse records like this one: 2,512
- Merck Sharp & Dohme LLC's enrollment: 89th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every US peer: $502,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 473 participants planned.
What is the ClinicalTrialStartPulse record for Merck Sharp & Dohme LLC?
Merck Sharp & Dohme LLC's Phase 3 study (NCT06356311) in Gastroesophageal Cancer, first posted 2024-04-10: enrollment closed (active, not recruiting) (2026-10-22), in an update posted 2026-10-22.
How does Merck Sharp & Dohme LLC compare to other ClinicalTrialStartPulse records?
Its enrollment of 473 sits in the upper half (89th percentile) of 8,879 records; the median is 80. It is fresh: dated 13 days ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
Merck Sharp & Dohme LLC vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Merck Sharp & Dohme LLC | US | 473 | 89th | 2026-10-22 |
| Janssen Research & Development, LLC | US | 539 | 90th | 2026-11-03 |
| Genmab | US | 600 | 91st | 2026-11-03 |
| Janssen-Cilag Ltd. | US | 288 | 82nd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: United States sites
How to monitor Merck Sharp & Dohme LLC and peer phase 3 records
Get new ClinicalTrialStartPulse records like Merck Sharp & Dohme LLC by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.